Tri­ci­da eye­ing sale, cost-cut­ting op­tions af­ter fail­ing high-stakes CKD wa­ger

Tri­ci­da is look­ing at all of its op­tions — not even two weeks af­ter watch­ing its stock nose­dive.

In an an­nounce­ment Wednes­day af­ter­noon, Tri­ci­da didn’t mince words.

“… the Board of Di­rec­tors has au­tho­rized Tri­ci­da to ini­ti­ate a re­view of strate­gic al­ter­na­tives to max­i­mize stake­hold­er val­ue. This strate­gic re­view may in­clude con­sid­er­a­tion of the sale of the Com­pa­ny and/or its as­sets.”

Tri­ci­da said that it is al­so in­ves­ti­gat­ing op­tions to re­duce its op­er­at­ing ex­pens­es, with plans to an­nounce the changes some­time over the next 3-4 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER